

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPENGATION-NO:	·········· PILII	NG DATE		FIRST-NAMED-INVENTOR-	_ \\T	torney-dooket-no-	- CONFIRMATION NO	
09/976,605		10/11/2001			Grant McFadden		50082/015002	3282	
	21559	7590	08/09/2004				EXAMINER		
	CLARK & ELBING LLP 101 FEDERAL STREET						WINKLER, ULRIKE		
	BOSTON, M						ART UNIT	PAPER NUMBER	
	•						1648		
						DAT	DATE MAILED: 08/09/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
Advisom, Astion	09/976,605	MCFADDEN ET AL.						
Advisory Action	Examiner	Art Unit						
	Ulrike Winkler	1648						
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence address						
THE REPLY FILED 21 June 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.								
PERIOD FOR REPLY [check either a) or b)]								
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
1.☑ A Notice of Appeal was filed on <u>21 June 2004</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.								
2. The proposed amendment(s) will not be entered because:								
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);								
(b) they raise the issue of new matter (see Note below);								
(c) ⊠ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or								
(d) they present additional claims without cancel								
NOTE: see attached sheet.								
3. Applicant's reply has overcome the following reject	tion(s):							
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a s	eparate, timely filed amendment						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:	5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly						
7. For purposes of Appeal, the proposed amendmen	7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.							
The status of the claim(s) is (or will be) as follows:								
Claim(s) allowed:								
Claim(s) objected to:	.,							
Claim(s) rejected: <u>11-13,15-18,21-26,32,33 and 47</u> .								
Claim(s) withdrawn from consideration: 1-10, 14, 2	<u>27-31, 34-48, 48-58</u> .							
8. The drawing correction filed on is a) app								
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)								

Application/Control Number: 09/976,605

Art Unit: 1648

Applicant's after final amendment submitted June 21, 2004 will not be entered because it would raise additional issues that would require further consideration. The claims remain rejected for the reason set out in the Office Action of December 19, 2003.

Applicant's amendment submitted June 21, 2004 to claim 11 does not clarify what specific activity the polypeptide needs to have, therefore, the specific function associated with the peptide is still not known. The ordinary artisan would not know whether the polypeptide encoded by the nucleic acid that has 99% sequence identity to SEQ ID NO:5 will be immunosuppressive or immunostimulatory? Is the peptide involved in cell proliferation? or cell inhibition? Does the peptide effect apoptosis? Decrease T cell stimulation? or what effect it would have on inflammation? It remains not clear what effect the polypeptide has on the immune system.

Applicant's additional claims submitted June 21, 2004, would be rejected under 35 U.S.C. § 101 because the claimed invention is directed to non-statutory subject matter. Claims 59-62 as written, does not sufficiently distinguish over the virus as it naturally exists because the claims do not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. See *Diamond v. Chakrabarty*, 447 U.S. 303, 206, USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g. by insertion of "isolated" or "purified" or "substantially pure" as defined on in the specification on page 17, lines 7-9. See M.P.E.P. § 2105.

Art Unit: 1648

Applicant's cancellation of claims 21, 32, 33 and 47 in the amendment submitted June 21, 2004, would overcome the claim rejections under 35 USC § 103 set out in the Office Action of December 19, 2003.

Papers related this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989). The Group 1600 Official Fax number is: (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Tech Center representative whose telephone number is (571)-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ulrike Winkler, Ph.D. whose telephone number is 571-272-0912. The examiner can normally be reached M-F, 8:30 am - 5 pm. The examiner can also be reached via email [ulrike.winkler@uspto.gov].

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached at 571-272-0902.

ULRIKE WINKLER, PH.D.
PRIMARY EXAMINER 8/6/04